Skip to main content Back to Top
Advertisement

8/9/2022

Mepivacaine Injection

Products Affected - Description

    • Polocaine injection, Fresenius Kabi, 1%, 50 mL multiple dose vial, NDC 63323-0283-57
    • Polocaine-MPF injection, Fresenius Kabi, 1%, 30 mL preservative-free vial, NDC 63323-0260-37
    • Polocaine-MPF injection, Fresenius Kabi, 1.5%, 30 mL preservative-free vial, NDC 63323-0293-37
    • Polocaine-MPF injection, Fresenius Kabi, 2%, 20 mL preservative-free vial, NDC 63323-0294-27

Reason for the Shortage

    • Fresenius Kabi had Polocaine on shortage due to manufacturing delays.
    • Pfizer stopped marketing Carbocaine in June 2022. The 2% Carbocaine 50 mL vials were discontinued in April 2021.

Available Products

    • Polocaine injection, Fresenius Kabi, 2%, 50 mL multiple dose vial, NDC 63323-0296-57

Estimated Resupply Dates

    • Fresenius Kabi has 1% Polocaine 50 mL vials on back order and the company estimates a release date of early-September 2022. The 1% Polocaine-MPF 30 mL vials are on back order and the company estimates a release date of late-August to early-September 2022. The 1.5% Polocaine-MPF 30 mL vials are on back order and the company estimates a release date of early- to mid-August 2022. The 2% Polocaine-MPF 20 mL vials are on back order and the company estimates a release date of early- to mid-August 2022.

Updated

Updated August 9, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 9, 2017 by Elyse MacDonald, PharmD, MS, BCPS. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.